http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이재심,김태형,김귀언,금기창,김용배 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.5
Objective: We aimed to assess the efficacy of neoadjuvant chemotherapy followed by surgery(NACT+S), and compared the clinical outcome with that of concurrent chemoradiotherapy(CCRT) in patients with International Federation of Gynecology and Obstetrics (FIGO) IB–IIBcervical cancer. Methods: We reviewed 85 patients with FIGO IB–IIB cervical cancer who received NACT+Sbetween 1989 and 2012, and compared them to 358 control patients who received CCRT. The clinical application of NACT was classified based on the following possible therapeuticbenefits: increasing resectability after NACT by reducing tumor size or negative conversionof node metastasis; downstaging adenocarcinoma regarded as relatively radioresistant; andpreservation of fertility through limited surgery after NACT. Results: Of 85 patients in the NACT+S group, the pathologic downstaging and completeresponse rates were 68.2% and 22.6%, respectively. Only two young patients underwentlimited surgery for preservation of fertility. Patients of the NACT+S group were younger,less likely to have node metastasis, and demonstrated a higher proportion of FIGO IB casesthan those of the CCRT group (p≤0.001). The 5-year locoregional control, progression-freesurvival, and overall survival rates in the NACT+S group were 89.7%, 75.6%, and 92.1%,respectively, which were not significantly different from the rates of 92.5%, 74%, and 84.9%observed in the CCRT group, respectively (p>0.05). Conclusion: NACT+S has no therapeutic advantages over CCRT, the standard treatment. Therefore, NACT+S should be considered only in selected patients through multidisciplinarydiscussion or clinical trial setting.